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1 were isolated. They were further separated after being dispersed in CH 2 Cl 2 (8 mL) and 2 centrifuged (12,000 rpm, 5 min), resulting in CD-MOF crystals in the precipitate and aluminum 3 stearate floating in the upper layer. The CD-MOF crystals in the precipitate were harvested and 4 dried for observation by SEM. 5 Drug loading (DL) is defined as the percent of drug measured in the drug-loaded CD-MOF or 6 CD-MOF/PAA microsphere samples and was calculated according to the following equation: 7 (S1) 8 The DL values of encapsulated drugs in CD-MOFs were measured by dissolving the sample (10 9 mg) in H 2 O (6 mL). The amounts of the drugs were analysed by HPLC (Agilent 1290, USA). For 10 CD-MOF/PAA composite microspheres, the drug loading was determined by dissolving the 11 microspheres (5 mg) in 67% MeOH (v/v, 3 mL) under sonication for 10 min and analysing the 12 solution by HPLC, equipped with a diode array detector. The analysis was carried out using a 13 Phenomenex C18 column (4.6 mm×150 mm, 5 μm) with a flow rate of 1.0 mL•min -1 and an 14 injection volume of 20 μL. IBU was detected at 263 nm and the column temperature was set at 15 35 °C. The mobile phase was composed of NaOAc buffer solution and MeCN (40:60, v/v). The 16 NaOAc buffer solution was obtained by dissolving NaOAc (6.13 g) in pure H 2 O (750 mL) and 17 adjusting the pH to 2.5 with glacial HOAc. For LPZ, the detection wavelength was set at 284 nm. 18 The mobile phase was composed of MeOH, H 2 O, TEA and H 3 PO 4 (640:360:5:1.5, pH was 19 adjusted to 7.3 with H 3 PO 4 ). The column temperature was maintained at 40 °C. 20 
In vitro Release of Drugs from Microspheres
21 Microspheres equivalent to 1 mg of IBU or LPZ were suspended in the release medium (50 mL) 22 containing polysorbate 80 (0.02%, w/v) and the suspension was maintained at 37 °C with a 23 stirring rate of 100 rpm. The release medium for IBU was PBS with pH 7.4, and that for LPZ
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1 was a carbonate buffer solution with pH 9.7 because of the instability of LPZ at pH of 7.4. These 2 release mediums were prepared according to Chinese Pharmacopeia 2010. Samples (1.0 mL) 3 were withdrawn at regular time intervals (0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h) and the same volume 4 of fresh medium was added. The concentration of the drug in each sample was determined by the 5 HPLC and the release percentage was calculated. Experiments were performed in triplicate. 6 7 The cytotoxicity of CD-MOF and CD-MOF/PAA composite microspheres was evaluated on 8 J774 macrophage cells using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 9 bromide) method. J774A.1 Cells (mouse macrophages, ATCC ® TIB-67 TM ) were grown in RMPI 10 1640 medium supplemented with 10% (v/v) fetal bovine serum (Gibco, USA), penicillin (100 11 U•mL -1 ) and streptomycin (100 μg•mL -1 ). Cells were maintained in a humidified incubator with 12 95% air and 5% CO 2 at 37 °C and seeded into 96-well microtiter plates at a density of 2000 13 cells•well -1 . After incubating overnight, samples (20 μL) at concentrations equivalent to the IBU 14 concentrations, ranging from 0.008 to 1.0 mg•mL -1 (with a five-fold dilution gradient) were 15 added to the medium and incubated for 24 h. Then, MTT (15 μL, 5 mg•mL -1 ) was added to the 16 cell culture medium and incubated for 4 h. Subsequently, the medium was replaced by Me 2 SO 17 (150 μL) to dissolve the insoluble crystals of formazan formed by living cells. The absorbance at 18 490 nm was read using a microplate reader (Multiskan GO, Thermo Fisher). Non-treated cells 19 were used as a control and the cell viability (%) was calculated using Eq. S2. Results were 20 expressed as mean ± standard deviation. 1 2 As described in the Section 2.1 on the "Preparation of Micron and Nanometer-Sized CD- 3 MOFs", the freshly obtained CD-MOF microcrystals and nanocrystals were washed with 4 i PrOH three times, and dried (37 °C) overnight for further use. The 1 H NMR spectrum 5 (Fig. S1) shows that there is no CTAB trapped in the CD-MOF nanocrystal after washing 6 the CD-MOF nanocrystals with i PrOH three times. In addition, MeOH (δ = 3.34 ppm) 7 was completely removed after the CD-MOF nanocrystals had been dried (37 °C) 8 overnight. 1 The crystallinity of CD-MOFs decreases (Fig. S2) after one day of incubation with DMF, 2 MeOH, Me 2 CO and EtOH at 70 °C. In the case of DMF and MeOH, the intensity for all 3 of the peaks decreased significantly and peaks at 16.7° disappeared, indicating the 4 instability of CD-MOF microcrystals in DMF and MeOH. This observation might be a 5 result of the relatively higher solubility of γ-CD in these two solvents. Fig. S2 also 6 illustrates the CD release profile for the CD-MOF microcrystals incubated in DMF at 70 7°C for three days. It should be noted that about 4% of the total amount of the organic 8 linker in the CD-MOF microcrystals was released after one day of incubation and 6% 9 after three days of incubation. 10 11 Fig. S2 a) PXRD Pattern of CD-MOF microcrystals incubated in different solvents at 70 12°C for one day. b) The CD release profile for the incubation in DMF at 70 °C for three 13 days. Error bars are based on repeating experiments on three batches of crystals. 14 15 The crystal size distributions of CD-MOF nanocrystals were characterised employing 16 both SEM and DLS techniques. The SEM images (Fig. 2b) show the CD-MOF 17 nanocrystals with diameters of 500-700 nm. The DLS result (Fig. S3) also reveals a 18 mean diameter of 650 nm, with a polydispersity index of 0.22. 4 The amount of drug-loaded into CD-MOFs of micron and nanometer sizes by 5 impregnation and co-crystallisation methods are listed in Table S2 . It is evident that IBU 6 loading into CD-MOF microcrystals decreased from 12.0 to 6.6% compared with that 7 obtained by the impregnation method. The LPZ loading in CD-MOF microcrystals 8 however, increased from 9.4 to 16.6%, when the impregnation method was replaced by 9 the co-crystallisation technique. In the case of the CD-MOF nanocrystals used to prepare 10 microspheres, drug loading by the co-crystallisation was equivalent to or higher than that 11 by the impregnation method. 11 In order to verify the presence of the drug-loaded CD-MOF crystals in the microspheres, 12 samples were treated with EtOH and CH 2 Cl 2 so as to remove and separate PAA and 13 aluminum tristearate crystals from the CD-MOFs. The SEM images (Fig. S9) Fig. S9 SEM Images of the drug-loaded CD-MOF nanocrystals encapsulated in PAA 5 composite microspheres after dissolving the microspheres with EtOH and removal of 6 aluminum stearate. 7 For the drug loading of microspheres shown in Table S4 , most of the values were 8 consistent with the theoretical values, except for the microspheres prepared by IBU raw 9 materials. The measured DL values were relatively higher than the theoretically 10 calculated ones, an observation which might result from the adhesion of PAA on the side 11 of the beaker and loss of PAA during microsphere preparation. In the FT-IR spectrum (Fig. S10) of blank PAA microspheres , the sharp peaks at 13 2800-3000, 1600-1800 and 800-900 cm -1 can be assigned to the characteristic stretching
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